Serevent Medicaid Study Could Offer Insight Into African-American Risk
Executive Summary
A Serevent Medicaid claims study could provide data on ethnic risk differences for respiratory-related severe adverse events with long-acting beta agonist bronchodilators, GlaxoSmithKline said during a July 13 meeting of FDA's Pulmonary-Allergy Drugs Advisory Committee
You may also be interested in...
Serevent, Foradil Use With Steroids Should Be Strongly Urged In Labeling
Labeling for GSK's Serevent and Novartis/Schering's Foradil should include a stronger recommendation that the long-acting beta agonist bronchodilators be used concomitantly with inhaled corticosteroids, FDA's Pulmonary-Allergy Drugs Advisory Committee said
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011